In a first-of-its-kind trial, researchers used tiny, simplified organs grown from patients’ cancer cells—so-called patient-derived organoids (PDOs)—to compare responses to anticancer agents in the laboratory and the clinic. The researchers focused on patients with chemotherapy-resistant ...
Patient‐derived organoids (PDOs) developed ex vivo and in vitro are increasingly used for therapeutic screening. They provide a more physiologically relevant model for drug discovery and development compared to traditional cell lines. However, several challenges remain to be addressed to fully realize...
Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank and paired...
In terms of cancer research applications, organoids-on-chip can help with various issues that the field is experiencing. First, high-throughput screening of anticancer drugs can be facilitated by simultaneously testing multiple compounds, along with different combinations of treatments or even drug regi...
Video S1. Time-lapse imaging of HSV-1 infection in ectocervical organoids, related to Figure 1 Video S2. Time-lapse imaging of HSV-1 infection in endocervical organoids, related to Figure 1 Document S1. Figures S1–S6 and Table S1 Table S2. Tumor and normal tissue-specific gene sets,...
Organoids (and cancer-derived organoids), are three-dimensional tissue-resembling cellular clusters derived from tissue or tumor specific stem cells that mimic the in vivo (tumor) characteristics, as well as (tumor) cell heterogeneity. Cancer organoids may further enhance the in vitro and in ...
Objective: To address whether patient-derived organoid (PDO) models can act as disease model substitutes for patients, and what is the maximum molecular extent to which they replace the original patient"s tumor, single-cell RNA sequencing(scRNA-seq) analyses were used to gain insights into the ...
Scale-up of Patient-Derived Organoids (PDOs) Cellesce uses its proprietary bioprocess and bioreactors for the expansion of human-derived normal and cancer PDOs for multiple applications, including drug screening. Learn moreContact us Research and Development ...
Boretto, M., Maenhoudt, N., Luo, X.et al.Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.Nat Cell Biol21, 1041–1051 (2019). https://doi.org/10.1038/s41556-019-0360-z ...